Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 25, 2022-- Gilead Sciences Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the combination of magrolimab plus...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials